Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury‘s companies to watch within the macrocycle chemistry space.
The reference came in Chris Cain‘s article, “Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals.”
MISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.
This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was distributed via Yahoo! Finance, Healthcare Global.com, marketwire and Digital Journal.
Hossein Rahnama, CEO of Flybits, a MaRS Innovation spin-off company, appeared on CBC’s Lang and O’Leary Exchange on August 24, 2012.
Watch Rahnama’s interview on CBC’s Media Player. The interview begins at the 13:40 mark and runs to 19:30.
Rahnama, who is also a professor at Ryerson University and and research director at Ryerson’s Digital Media Zone, was recently named to the MIT Technology Review’s prestigious 35 Inventors Under 35 list for 2012 along with fellow MaRS Innovation inventor Joyce Poon.
He describes his context-aware mobile technology, the importance of adapting research to solve real-world problems, the advantages to running a start-up in Toronto, and growing Flybits while keeping the business in Canada.
Professors Joyce Poon and Hossein Rahnama, who each have inventions within MaRS Innovation’s portfolio of spin-off companies and licenseable technologies, have been named to the MIT Technology Review‘s prestigious 35 Inventors Under 35 list for 2012.
Poon, an assistant professor of electrical and computer engineering at the University of Toronto, was recognized for, according to MIT’s Technology Review, “creating new optical modulators with microscopic loop-the-loops through which light can shuttle data between servers and even from chip to chip within a single server.” She is working with MaRS Innovation to license her technology.
Andrew Sinclair, CEO of OtoSim Inc. and a senior director at MaRS Innovation, describes some of the unexpected twists and turns OtoSim has weathered in bringing their product to market in…
Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada’s innovation gap and the shortage of Canadian venture capital:
One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.
“Everybody told us — institutions, industry — that they will not participate unless government has a piece of the pie. So governments have to participate, certainly in the early stage,” he said.
Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, was quoted in a National Post article, published August 13, probing whether Canadian research is passing the commercialization test.
Here’s an excerpt:
While academics have often been accused of being disconnected from the real world and consuming themselves with the theoretical, it’s hard to imagine they would be able to get away with squandering funding dollars on things that make them go hmmm, particularly in light of the hyper focus on fiscal prudence.
Indeed, those who are intimately involved in attempting to bridge the commercialization gap agree that the old system of leaving university professors to their own devices had long ago been shelved in favour of a more judicious approach.
Joel Liederman, vice president of Business Development and Physical Sciences at MaRS Innovation, says there’s no doubt that much of the R&D being performed in Canada never makes it past the patent stage, but not because its origins were founded on theory instead of commercial need.
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can…
The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.
Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt:…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca